BioLineRx (BLRX) director Dar Rami reports multiple employee stock option grants

Rhea-AI Filing Summary

BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.

One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Dar Rami

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 1,080,000 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Key Figures

Option grant 1: 1,080,000 shares at $0.085 Option grant 2: 360,000 shares at $0.081 Option grant 3: 360,000 shares at $0.085 +3 more

6 metrics

Option grant 1 1,080,000 shares at $0.085 Employee Stock Option, expires July 3, 2032

Option grant 2 360,000 shares at $0.081 Employee Stock Option, expires July 3, 2033

Option grant 3 360,000 shares at $0.085 Employee Stock Option, expires July 3, 2032

Option grant 4 2,055,000 shares at $0.052 Employee Stock Option, expires August 14, 2034

Vested portion of 2024 grant 856,200 options vested Vested as of appointment date on October 1, 2024

Unvested portion of 2024 grant 1,198,800 options unvested To vest in seven equal quarterly installments

Key Terms

Employee Stock Option (Right to Buy), 2003 Amended and Restated Share Incentive Plan, Ordinary Shares, Section 102 of the Israeli Tax Ordinance, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

2003 Amended and Restated Share Incentive Plan financial

"Options granted under the 2003 Amended and Restated Share Incentive Plan."

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Section 102 of the Israeli Tax Ordinance regulatory

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance,"

vesting financial

"The remaining 1,198,800 options will vest in 7 equal quarterly installments,"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dar Rami

(Last) (First) (Middle)

C/O BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/03/2022	07/03/2032	Ordinary Shares	1,080,000	$0.085	D
Employee Stock Option (Right to Buy)(1)(3)	10/03/2023	07/03/2033	Ordinary Shares	360,000	$0.081	D
Employee Stock Option (Right to Buy)(1)(4)	10/03/2024	07/03/2032	Ordinary Shares	360,000(6)	$0.085	D
Employee Stock Option (Right to Buy)(1)(5)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000(6)	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.

3. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.

4. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.

5. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

6. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Rami Dar	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioLineRx (BLRX) Form 3 for Dar Rami show?

The Form 3 shows that director Dar Rami holds several employee stock options over BioLineRx Ordinary Shares. These options have exercise prices from $0.052 to $0.085 and expiration dates between 2032 and 2034, all granted under the 2003 Amended and Restated Share Incentive Plan.

How many BioLineRx (BLRX) shares are covered by Dar Rami’s options?

The filing lists option grants over 1,080,000, 360,000, 360,000 and 2,055,000 underlying Ordinary Shares. Each grant is tied to a specific exercise price and expiration date, reflecting Dar Rami’s potential future ownership if these employee stock options are exercised.

What are the exercise prices of Dar Rami’s BioLineRx (BLRX) stock options?

The reported employee stock options carry exercise prices of $0.085, $0.081, $0.085 and $0.052 per Ordinary Share. These exercise prices, disclosed in the Form 3, define the cost at which Dar Rami can purchase BioLineRx shares through the respective option grants.

How do Dar Rami’s BioLineRx (BLRX) options vest over time?

The filing notes one grant dated October 1, 2024, where 856,200 options were vested as of the appointment date. The remaining 1,198,800 options from this grant will vest in seven equal quarterly installments, subject to Dar Rami’s continued service to BioLineRx at each vesting date.

When do Dar Rami’s BioLineRx (BLRX) stock options expire?

The option grants reported in the Form 3 have expiration dates of July 3, 2032, July 3, 2033, July 3, 2032 and August 14, 2034. These dates indicate the final day on which each employee stock option can be exercised for BioLineRx Ordinary Shares.

Under which plan were Dar Rami’s BioLineRx (BLRX) options granted?

All of the reported employee stock options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. A footnote explains that, to qualify for certain Section 102 Israeli tax benefits, securities issued to employees must be registered in a trustee’s name.